WO2004051280A3 - Bestimmung agonistischer autoantikörper - Google Patents

Bestimmung agonistischer autoantikörper Download PDF

Info

Publication number
WO2004051280A3
WO2004051280A3 PCT/DE2003/003988 DE0303988W WO2004051280A3 WO 2004051280 A3 WO2004051280 A3 WO 2004051280A3 DE 0303988 W DE0303988 W DE 0303988W WO 2004051280 A3 WO2004051280 A3 WO 2004051280A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
agonistic autoantibodies
autoantibodies
agonistic
peptides
Prior art date
Application number
PCT/DE2003/003988
Other languages
English (en)
French (fr)
Other versions
WO2004051280A2 (de
Inventor
Gerd Wallukat
Original Assignee
Max Delbrueck Centrum
Gerd Wallukat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10327066A external-priority patent/DE10327066A1/de
Application filed by Max Delbrueck Centrum, Gerd Wallukat filed Critical Max Delbrueck Centrum
Priority to US10/536,552 priority Critical patent/US7741050B2/en
Priority to AU2003293004A priority patent/AU2003293004A1/en
Priority to EP03788849A priority patent/EP1570272A2/de
Publication of WO2004051280A2 publication Critical patent/WO2004051280A2/de
Publication of WO2004051280A3 publication Critical patent/WO2004051280A3/de
Priority to US11/948,064 priority patent/US20090023662A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/971—Capture of complex after antigen-antibody reaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Detektion von krankheitsassoziierten Autoantikörpern, die extrazelluläre Strukturen von G-Protein-gekoppelten Rezeptoren erkennen, und die Verwendung von Peptiden, die diese Loops oder Fragmente dieser umfassen, zur Behandlung von Autoimmunkrankheiten.
PCT/DE2003/003988 2002-11-29 2003-11-28 Bestimmung agonistischer autoantikörper WO2004051280A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/536,552 US7741050B2 (en) 2002-11-29 2003-11-28 Identification of agonistic autoantibodies
AU2003293004A AU2003293004A1 (en) 2002-11-29 2003-11-28 Identification of agonistic autoantibodies
EP03788849A EP1570272A2 (de) 2002-11-29 2003-11-28 Bestimmung agonistischer autoantikörper
US11/948,064 US20090023662A1 (en) 2002-11-29 2007-11-30 Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10256897 2002-11-29
DE10256897.9 2002-11-29
DE10303120 2003-01-27
DE10303120.0 2003-01-27
DE10327066.3 2003-06-13
DE10327066A DE10327066A1 (de) 2002-11-29 2003-06-13 Bestimmung agonistischer Autoantikörper

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/948,064 Division US20090023662A1 (en) 2002-11-29 2007-11-30 Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection

Publications (2)

Publication Number Publication Date
WO2004051280A2 WO2004051280A2 (de) 2004-06-17
WO2004051280A3 true WO2004051280A3 (de) 2005-01-06

Family

ID=32474857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/003988 WO2004051280A2 (de) 2002-11-29 2003-11-28 Bestimmung agonistischer autoantikörper

Country Status (4)

Country Link
US (1) US7741050B2 (de)
EP (1) EP1570272A2 (de)
AU (1) AU2003293004A1 (de)
WO (1) WO2004051280A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123929A1 (de) * 2001-05-11 2002-11-21 Celltrend Gmbh Verfahren zur Vorhersage eines Transplantatabstoßungsrisikos und immunologischer Testkit
EP1597271B1 (de) * 2003-01-31 2013-03-06 Max-Delbrück-Centrum Für Molekulare Medizin Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung
EP1832600A1 (de) * 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptide gegen Autoantikörper verbunden mit Glaukom und deren Verwendung
PL1884775T3 (pl) * 2006-08-04 2010-06-30 Celltrend Gmbh Sposób rozpoznawania chorób związanych z przeciwciałem przeciwko receptorowi AT 1
EP1884776A1 (de) * 2006-08-04 2008-02-06 Celltrend GmbH Verfahren zur diagnose einer krankheit, die auf der gegenwart des anti-endothelin-antikörpers beruht
WO2008151847A1 (en) * 2007-06-13 2008-12-18 Max-Delbrück-Centrum für Molekulare Medizin Autoantibody binding peptides and their use for the treatment of vascular diseases
JPWO2009044650A1 (ja) * 2007-10-05 2011-02-03 株式会社カネカ 免疫グロブリンおよび／または免疫グロブリン複合体に結合活性を有する、標識されたペプチド、および上記ペプチドを用いた免疫グロブリンの検出方法または測定方法
EP2080519A1 (de) 2008-01-15 2009-07-22 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Peptide mit Bindungsaffinität an einen Antikörper, der ein Epitop in einer Alpha1-Schleife2 oder einer Beta2-Schleife 1 eines Adrenorezeptors erkennt
EP2199305A1 (de) * 2008-12-18 2010-06-23 Max-Delbrück-Centrum Peptide gegen Autoantikörper, die mit CRPS assoziiert sind, und Verwendung dieser Peptide
TWI546122B (zh) * 2011-02-25 2016-08-21 東麗股份有限公司 血液成分吸附用載體及血液成分吸附管柱
WO2015117956A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against par1
CN109467599B (zh) * 2017-09-08 2021-06-04 武汉华纪元生物技术开发有限公司 短肽atr001以及由短肽制备具有偏向性调节at1r功能的单克隆抗体和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19826442A1 (de) * 1998-06-02 1999-12-09 Affina Immuntechnik Gmbh Rational designte Peptide, ihre Herstellung und ihre Verwendung
WO2001021660A1 (de) * 1999-09-21 2001-03-29 Affina Immuntechnik Gmbh Peptide gegen dcm hervorrufende autoantikörper
WO2004067549A2 (de) * 2003-01-31 2004-08-12 Max-Delbrück-Centrum für Molekulare Medizin Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8102178A (nl) * 1981-05-02 1982-12-01 Stichting Centraal Lab Werkwijze voor het aantonen van tegen bepaalde antigenen gerichte antistoffen, alsmede inrichting en reagentia voor het uitvoeren van deze werkwijze.
EP1141018A2 (de) 1998-12-24 2001-10-10 Max-Delbrück-Centrum Für Molekulare Medizin Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
DE10041560A1 (de) 2000-08-24 2002-03-07 Max Delbrueck Centrum Peptide des alpha1-adrenergen Rezeptors und ihre Verwendung bei Psoriasis
DE10123929A1 (de) 2001-05-11 2002-11-21 Celltrend Gmbh Verfahren zur Vorhersage eines Transplantatabstoßungsrisikos und immunologischer Testkit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19826442A1 (de) * 1998-06-02 1999-12-09 Affina Immuntechnik Gmbh Rational designte Peptide, ihre Herstellung und ihre Verwendung
WO2001021660A1 (de) * 1999-09-21 2001-03-29 Affina Immuntechnik Gmbh Peptide gegen dcm hervorrufende autoantikörper
WO2004067549A2 (de) * 2003-01-31 2004-08-12 Max-Delbrück-Centrum für Molekulare Medizin Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BELCH J J F: "RAYNAUD'S PHENOMENON", CURRENT OPINION IN RHEUMATOLOGY, vol. 3, no. 6, 1991, pages 960 - 966, XP009036439, ISSN: 1040-8711 *
BOROS PETER ET AL: "Specificity and class distribution of Fc-gamma-R-specific autoantibodies in patients with autoimmune disease", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 152, 1994, pages 302 - 306, XP002138629, ISSN: 0022-1767 *
FU MICHAEL L X ET AL: "A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 78, no. 2, 1996, pages 203 - 207, XP002278138, ISSN: 0090-1229 *
MACFARLANE S R ET AL: "Proteinase-activated receptors", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 53, no. 2, June 2001 (2001-06-01), pages 245 - 282, XP002234540, ISSN: 0031-6997 *
MARINO MARIA ET AL: "Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide", NATURE BIOTECHNOLOGY, vol. 18, no. 7, July 2000 (2000-07-01), pages 735 - 739, XP002278139, ISSN: 1087-0156 *
STAUDT ALEXANDER ET AL: "Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy.", CIRCULATION, vol. 106, no. 19, 5 November 2002 (2002-11-05), pages 2448 - 2453, XP002278136, ISSN: 0009-7322 (ISSN print) *
WALLUKAT G ET AL: "ANTI-BETA1-ADRENOCEPTOR AUTOANTIBODIES WITH CHRONOTROPIC ACTIVITY FROM THE SERUM OF PATIENTS WITH DILATED CARDIOMYOPATHY: MAPPING OF EPITOPES IN THE FIRST AND SECOND EXTRACELLULAR LOOPS", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 27, 1995, pages 397 - 406, XP000985473, ISSN: 0022-2828 *
WALLUKAT GERD ET AL: "Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy", HERZ, vol. 25, no. 3, 2000, pages 261 - 266, XP002278137, ISSN: 0340-9937 *
WALLUKAT GERD ET AL: "Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy.", NEW ENGLAND JOURNAL OF MEDICINE, vol. 347, no. 22, 28 November 2002 (2002-11-28), pages 1806, XP009029900, ISSN: 0028-4793 (ISSN print) *
WALLUKAT GERD ET AL: "Spontaneously beating neonatal rat heart myocyte culture: A model to characterize angiotensin II AT1 receptor autoantibodies in patients with preeclampsia.", IN VITRO CELLULAR AND DEVELOPMENTAL BIOLOGY ANIMAL, vol. 38, no. 7, 2002, pages 376 - 377, XP002278135, ISSN: 1071-2690 *

Also Published As

Publication number Publication date
WO2004051280A2 (de) 2004-06-17
US7741050B2 (en) 2010-06-22
AU2003293004A1 (en) 2004-06-23
US20060263835A1 (en) 2006-11-23
EP1570272A2 (de) 2005-09-07

Similar Documents

Publication Publication Date Title
WO2004051280A3 (de) Bestimmung agonistischer autoantikörper
EP1270724A3 (de) Guanosin Triphosphat-bindende Protein-gekoppelte Rezeptoren
WO2008031577A8 (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
WO2001077172A3 (en) Non-endogenous, constitutively activated known g protein-coupled receptors
WO2001098351A3 (en) G-protein coupled receptors
WO2010016766A3 (en) Antibodies recognizing endogenous human lgr5 and/or lgr6
WO2006066568A3 (de) Monokonale agonistische anti-ctla-4 antikörper
EP1440981A3 (de) Vollständige humane cDNS
MX2010009505A (es) Anticuerpos monoclonales contra la proteina rgm a y usos de los mismos.
WO2004096154A3 (en) Methods for treating degenerative diseases/injuries
TW200606395A (en) Optical tracking sensor method
WO2002084286A1 (fr) Procede de criblage
WO2007139921A3 (en) N-oxides of kappa opioid receptor peptides
WO2003027228A3 (en) Receptors and membrane-associated proteins
AU2002358274A1 (en) Methods for determining polypeptide structure, function or pharmacophore from comparison of polypeptide sequences
WO2002010387A3 (en) G-protein coupled receptors
WO2004070025A3 (en) Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
WO2003046147A3 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
WO2003088924A3 (en) Phosphoinositide 3-kinase mediated inhibition of gpcrs
WO2003020887A3 (en) Gene identification
WO2002063004A3 (en) G-protein coupled receptors
WO2003025130A3 (en) Receptors and membrane-associated proteins
WO2002057454A3 (en) Receptors and membrane-associated proteins
WO2000014222A3 (en) Gabab receptor subtypes gabab-r1c and gabab-r2 and heterodimers thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003788849

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003788849

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006263835

Country of ref document: US

Ref document number: 10536552

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWP Wipo information: published in national office

Ref document number: 10536552

Country of ref document: US